Baseline patient characteristics in different subsets of primary refractory disease
| Variable . | MER (N = 949) . | LEO (N = 2755) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PPD (n = 40) . | EOT PR (n = 40) . | Early relapse (<12 mos) (n = 52) . | Total (n = 132) . | P† . | PPD (n = 145) . | EOT PR (n = 66) . | Early relapse (<12 mos) (n = 97) . | Total (n = 308) . | P . | |
| n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | |||
| Age at diagnosis, y | .754 | |||||||||
| Median (range) | 59.5 (19-80) | 62.5 (24-84) | 60.0 (21-83) | 60.0 (19-84) | 63 (19-88) | 62 (28-90) | 64 (25-83) | 63 (19-90) | .829 | |
| Sex | .448 | .996 | ||||||||
| F | 19 (47.5) | 8 (20.0) | 20 (38.5) | 47 (35.6) | 50 (34.7) | 23 (34.8) | 35 (36.5) | 108 (35.3) | ||
| Race | .754 | .485 | ||||||||
| White | 36 (90.0) | 37 (92.5) | 50 (96.2) | 123 (93.2) | 127 (88.2) | 57 (86.4) | 80 (83.3) | 264 (86.3) | ||
| African American | 0 (0.0) | 1 (2.5) | 0 (0.0) | 1 (0.8) | 10 (6.9) | 4 (6.1) | 6 (6.3) | 20 (6.5) | ||
| Unknown/not reported | 4 (10.0) | 2 (5.0) | 2 (3.8) | 8 (6.1) | 4 (2.8) | 1 (1.5) | 4 (4.2) | 9 (2.9) | ||
| Ethnicity | .754 | .889 | ||||||||
| Not Hispanic/Latinx | 33 (82.5) | 37 (92.5) | 47 (90.4) | 117 (88.6) | 126 (87.5) | 60 (90.9) | 84 (87.5) | 270 (88.2) | ||
| Hispanic/Latinx | 0 | 0 | 0 | 0 | 15 (11.0) | 6 (9.1) | 11 (11.5) | 32 (10.5) | ||
| Unknown/not reported | 7 (17.5) | 3 (7.5) | 5 (9.6) | 15 (11.4) | 3 (2.1) | 0 (0) | 1 (1) | 4 (1.3) | ||
| ECOG PS | .853 | .996 | ||||||||
| <2 | 35 (87.5) | 33 (82.5) | 45 (86.5) | 113 (85.6) | 104 (77.0) | 47 (77.0) | 69 (77.5) | 220 (77.2) | ||
| LDH | .782 | .485 | ||||||||
| >Normal | 26 (78.8) | 24 (77.4) | 41 (85.4) | 91 (81.3) | 87 (76.3) | 37 (66.1) | 72 (80.9) | 196 (75.7) | ||
| Extranodal sites | .754 | .829 | ||||||||
| ≤1 | 24 (63.2) | 31 (77.5) | 32 (61.5) | 87 (66.9) | 92 (64.8) | 46 (70.8) | 58 (61.70) | 196 (65.1) | ||
| Ann Arbor stage | .782 | .816 | ||||||||
| III to IV | 32 (80.0) | 29 (72.5) | 37 (71.2) | 98 (74.2) | 107 (80.5) | 46 (76.7) | 80 (85.1) | 233 (81.2) | ||
| IPI group | .754 | .485 | ||||||||
| 0 to 1, low | 9 (22.5) | 11 (27.5) | 10 (19.2) | 30 (22.7) | 37 (25.7) | 19 (28.8) | 14 (14.6) | 70 (22.9) | ||
| 2, low intermediate | 10 (25.0) | 13 (32.5) | 12 (23.1) | 35 (26.5) | 35 (24.3) | 19 (28.8) | 22 (22.9) | 76 (24.8) | ||
| 3, high intermediate | 15 (37.5) | 7 (17.5) | 23 (44.2) | 45 (34.1) | 42 (29.2) | 15 (22.7) | 35 (36.5) | 92 (30.1) | ||
| 4 to 5, high | 6 (15.0) | 9 (22.5) | 7 (13.5) | 22 (16.7) | 30 (20.8) | 13 (19.7) | 25 (26.0) | 68 (22.2) | ||
| Diagnosis to treatment interval | .782 | .889 | ||||||||
| Median (range), days | 12.5 (2-43) | 13 (2-41) | 12.5 (0-40) | 12.5 (0-43) | 15 (1-55) | 16 (3-56) | 16.5 (1-92) | 15 (1-92) | ||
| Cell of origin | .980 | .485 | ||||||||
| Known | ||||||||||
| Non-GCB | 15 (50.0) | 12 (46.2) | 15 (48.4) | 42 (48.3) | 32 (41.5) | 20 (39.2) | 30 (45.4) | 82 (42.2) | ||
| GCB | 15 (50.0) | 14 (53.8) | 16 (51.6) | 45 (51.7) | 45 (58.5) | 31 (60.8) | 36 (54.6) | 112 (57.4) | ||
| Unknown/not done | 1 | 1 | 2 | 4 | 29 | 8 | 11 | 48 | ||
| Double hit/triple hit | .832 | .485 | ||||||||
| Known | ||||||||||
| Yes | 4 (19.0) | 1 (5) | 3 (12) | 8 (12.1) | 23 (27.3) | 7 (14.9) | 11 (16.4) | 41 (20.7) | ||
| No | 17 (81.0) | 19 (95) | 22 (88) | 58 (87.9) | 61 (72.7) | 40 (85.1) | 56 (83.6) | 157 (79.3) | ||
| Unknown/not done | 19 | 20 | 27 | 66 | 61 | 19 | 30 | 110 | ||
| Double expressor | .754 | .889 | ||||||||
| Known | ||||||||||
| Yes | 6 (30) | 3 (20) | 5 (33.3) | 14 (28.0) | 25 (43.1) | 12 (37.5) | 19 (41.3) | 56 (41.2) | ||
| No | 14 (70) | 12 (80) | 10 (66.7) | 36 (72.0) | 33 (56.9) | 20 (62.5) | 27 (58.7) | 80 (58.8) | ||
| Unknown/not done | 20 | 25 | 37 | 82 | 87 | 34 | 50 | 170 | ||
| 1L treatment | .431 | .485 | ||||||||
| R-CHOP | 27 (67.5) | 32 (80.0) | 37 (71.2) | 96 (72.7) | 112 (77.2) | 46 (70.8) | 64 (66.7) | 221 (72.7) | ||
| Other IC∗ | 13 (32.5) | 8 (20.0) | 15 (28.8) | 36 (27.3) | 33 (22.8) | 19 (29.2) | 32 (33.3) | 83 (27.3) | ||
| Variable . | MER (N = 949) . | LEO (N = 2755) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PPD (n = 40) . | EOT PR (n = 40) . | Early relapse (<12 mos) (n = 52) . | Total (n = 132) . | P† . | PPD (n = 145) . | EOT PR (n = 66) . | Early relapse (<12 mos) (n = 97) . | Total (n = 308) . | P . | |
| n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | |||
| Age at diagnosis, y | .754 | |||||||||
| Median (range) | 59.5 (19-80) | 62.5 (24-84) | 60.0 (21-83) | 60.0 (19-84) | 63 (19-88) | 62 (28-90) | 64 (25-83) | 63 (19-90) | .829 | |
| Sex | .448 | .996 | ||||||||
| F | 19 (47.5) | 8 (20.0) | 20 (38.5) | 47 (35.6) | 50 (34.7) | 23 (34.8) | 35 (36.5) | 108 (35.3) | ||
| Race | .754 | .485 | ||||||||
| White | 36 (90.0) | 37 (92.5) | 50 (96.2) | 123 (93.2) | 127 (88.2) | 57 (86.4) | 80 (83.3) | 264 (86.3) | ||
| African American | 0 (0.0) | 1 (2.5) | 0 (0.0) | 1 (0.8) | 10 (6.9) | 4 (6.1) | 6 (6.3) | 20 (6.5) | ||
| Unknown/not reported | 4 (10.0) | 2 (5.0) | 2 (3.8) | 8 (6.1) | 4 (2.8) | 1 (1.5) | 4 (4.2) | 9 (2.9) | ||
| Ethnicity | .754 | .889 | ||||||||
| Not Hispanic/Latinx | 33 (82.5) | 37 (92.5) | 47 (90.4) | 117 (88.6) | 126 (87.5) | 60 (90.9) | 84 (87.5) | 270 (88.2) | ||
| Hispanic/Latinx | 0 | 0 | 0 | 0 | 15 (11.0) | 6 (9.1) | 11 (11.5) | 32 (10.5) | ||
| Unknown/not reported | 7 (17.5) | 3 (7.5) | 5 (9.6) | 15 (11.4) | 3 (2.1) | 0 (0) | 1 (1) | 4 (1.3) | ||
| ECOG PS | .853 | .996 | ||||||||
| <2 | 35 (87.5) | 33 (82.5) | 45 (86.5) | 113 (85.6) | 104 (77.0) | 47 (77.0) | 69 (77.5) | 220 (77.2) | ||
| LDH | .782 | .485 | ||||||||
| >Normal | 26 (78.8) | 24 (77.4) | 41 (85.4) | 91 (81.3) | 87 (76.3) | 37 (66.1) | 72 (80.9) | 196 (75.7) | ||
| Extranodal sites | .754 | .829 | ||||||||
| ≤1 | 24 (63.2) | 31 (77.5) | 32 (61.5) | 87 (66.9) | 92 (64.8) | 46 (70.8) | 58 (61.70) | 196 (65.1) | ||
| Ann Arbor stage | .782 | .816 | ||||||||
| III to IV | 32 (80.0) | 29 (72.5) | 37 (71.2) | 98 (74.2) | 107 (80.5) | 46 (76.7) | 80 (85.1) | 233 (81.2) | ||
| IPI group | .754 | .485 | ||||||||
| 0 to 1, low | 9 (22.5) | 11 (27.5) | 10 (19.2) | 30 (22.7) | 37 (25.7) | 19 (28.8) | 14 (14.6) | 70 (22.9) | ||
| 2, low intermediate | 10 (25.0) | 13 (32.5) | 12 (23.1) | 35 (26.5) | 35 (24.3) | 19 (28.8) | 22 (22.9) | 76 (24.8) | ||
| 3, high intermediate | 15 (37.5) | 7 (17.5) | 23 (44.2) | 45 (34.1) | 42 (29.2) | 15 (22.7) | 35 (36.5) | 92 (30.1) | ||
| 4 to 5, high | 6 (15.0) | 9 (22.5) | 7 (13.5) | 22 (16.7) | 30 (20.8) | 13 (19.7) | 25 (26.0) | 68 (22.2) | ||
| Diagnosis to treatment interval | .782 | .889 | ||||||||
| Median (range), days | 12.5 (2-43) | 13 (2-41) | 12.5 (0-40) | 12.5 (0-43) | 15 (1-55) | 16 (3-56) | 16.5 (1-92) | 15 (1-92) | ||
| Cell of origin | .980 | .485 | ||||||||
| Known | ||||||||||
| Non-GCB | 15 (50.0) | 12 (46.2) | 15 (48.4) | 42 (48.3) | 32 (41.5) | 20 (39.2) | 30 (45.4) | 82 (42.2) | ||
| GCB | 15 (50.0) | 14 (53.8) | 16 (51.6) | 45 (51.7) | 45 (58.5) | 31 (60.8) | 36 (54.6) | 112 (57.4) | ||
| Unknown/not done | 1 | 1 | 2 | 4 | 29 | 8 | 11 | 48 | ||
| Double hit/triple hit | .832 | .485 | ||||||||
| Known | ||||||||||
| Yes | 4 (19.0) | 1 (5) | 3 (12) | 8 (12.1) | 23 (27.3) | 7 (14.9) | 11 (16.4) | 41 (20.7) | ||
| No | 17 (81.0) | 19 (95) | 22 (88) | 58 (87.9) | 61 (72.7) | 40 (85.1) | 56 (83.6) | 157 (79.3) | ||
| Unknown/not done | 19 | 20 | 27 | 66 | 61 | 19 | 30 | 110 | ||
| Double expressor | .754 | .889 | ||||||||
| Known | ||||||||||
| Yes | 6 (30) | 3 (20) | 5 (33.3) | 14 (28.0) | 25 (43.1) | 12 (37.5) | 19 (41.3) | 56 (41.2) | ||
| No | 14 (70) | 12 (80) | 10 (66.7) | 36 (72.0) | 33 (56.9) | 20 (62.5) | 27 (58.7) | 80 (58.8) | ||
| Unknown/not done | 20 | 25 | 37 | 82 | 87 | 34 | 50 | 170 | ||
| 1L treatment | .431 | .485 | ||||||||
| R-CHOP | 27 (67.5) | 32 (80.0) | 37 (71.2) | 96 (72.7) | 112 (77.2) | 46 (70.8) | 64 (66.7) | 221 (72.7) | ||
| Other IC∗ | 13 (32.5) | 8 (20.0) | 15 (28.8) | 36 (27.3) | 33 (22.8) | 19 (29.2) | 32 (33.3) | 83 (27.3) | ||
Early relapse defined as relapse within 12 months after 1L treatment.
Double-hit/triple-hit defined as MYC rearrangement with BCL2 and/or BCL6; and double expressor defined as expression of MYC and BCL2 by immunohistochemistry.
ECOG PS, Eastern Cooperative Oncology Group performance status; F, female; GCB, germinal center B cell; LDH, lactate dehydrogenase; mos, months.
Other IC: includes more intensive 1L chemotherapy including Rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate and cytarabine therapy as part of an investigational clinical trial (eg, R2-CHOP).
False discovery rate correction applied to all analyses.